Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement
Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.
BioSpace20h
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
Hosted on MSN23h
Breakthrough sickle cell drug causes excitement
A groundbreaking sickle cell disease treatment has been approved for use in the UK's National Health Service (NHS). The treatment offers patients with severe forms of the condition hope for a ...